Krilogy Financial LLC Purchases 5,864 Shares of Zoetis Inc. $ZTS

Key Points

• Krilogy Financial LLC increased its holdings in Zoetis Inc. by 49.4%, purchasing an additional 5,864 shares during the 2nd quarter, bringing their total ownership to 17,738 shares valued at $2,766,000.
• Zoetis reported $1.76 earnings per share (EPS) for the last quarter, surpassing expectations and showing a revenue increase of 4.2% year-over-year, totaling $2.46 billion.
• The stock has a consensus rating of "Moderate Buy" from analysts, with a target price averaging around $200.88, reflecting a mixed outlook following various upgrades and downgrades from research firms.

Krilogy Financial LLC lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 49.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,738 shares of the company's stock after purchasing an additional 5,864 shares during the quarter. Krilogy Financial LLC's holdings in Zoetis were worth $2,766,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp increased its holdings in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its holdings in shares of Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after purchasing an additional 312,746 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE ZTS opened at $146.34 on Tuesday. The company has a 50-day simple moving average of $152.10 and a two-hundred day simple moving average of $157.06. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The firm has a market cap of $64.85 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 2.38 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The company's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Argus reiterated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.